The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback